登录注册

Humoral IgG1 responses to tumor antigens underpin clinical outcomes in immune checkpoint blockade

Nature Medicine

Humoral responses, particularly IgG1, to tumor antigens are associated with clinical outcomes in patients treated with immune checkpoint blockade. Plasma cell profiling after PD-1 blockade reveals tumor-specific antibodies targeting citrullinated proteins.

Related products

Catalog No.	Product Name	Description	Target
HY328026	Anti-Human IL-6 Reference Antibody (Ziltivekimab	Research Grade Ziltivekimab (HY328026) is a humanized monoclonal antibody detecting Hybridoma growth factor in ELISA, Bioactivity: FACS, Functional assay, Research in vivo. Suitable for Human. Highlights ●Multi-Application — Validated across multiple applications.	B-cell stimulatory factor 2, BSF-2, CDF, CTL differentiation factor, Hybridoma growth factor, IFN-beta-2, IFNB2, IL-6, IL6, Interferon beta-2, Interleukin-6

7X24小时产品咨询热线：027--87433958(9:00-18:00)，或扫描下方产品专员二维码或在线留言
武汉东湖新技术开发区神墩四路666号研发楼B区3层东

24小时产品查询
扫一扫关注我们
专属渠道经理

鄂ICP备2023002448号-2

重组蛋白

抗体

试剂盒

实验相关试剂

Humoral IgG1 responses to tumor antigens underpin clinical outcomes in immune checkpoint blockade